Per the small published trial cohort + thin biohacker community reports at 2-4 mg SC daily × 4 weeks:

• Days 1-7 (first week): Typically nothing perceptible. The mechanism is signaling at injured-tissue receptors, not producing acute neurotransmitter effects. Possible mild fatigue or lethargy in the first few injections (also reported with TB-500); some users report a faint warm/flushed feeling at injection. Mild injection-site soreness, transient bruising — clears in <24h.
• Week 2: Subtle baseline shift. Users who are paying close attention may notice slightly reduced burning/tingling intensity, slightly improved autonomic function (less night sweating, less orthostatic lightheadedness if those were baseline issues). Many users report nothing perceptible at this point.
• Weeks 3-4 (peak): This is where the trial cohort showed the clearest effect signal and where subjective experience tends to consolidate. Users with a clear small-fiber-pattern target (burning pain, paresthesia, autonomic complaints) report meaningful symptom reduction — typically described as "the burning is just less" or "the tingling doesn't dominate my attention anymore." Effect is gradual, not a step-change. Effect on objective sensory function (2-point discrimination, light-touch threshold) is more variable.
• Post-cycle (weeks 1-4 after stop): Reports vary. Some users describe persistent benefit consistent with a true tissue-level repair effect; others see gradual return of baseline symptoms within 2-4 weeks of stopping. The pattern suggests ARA-290 is at least partly producing structural / inflammatory-state changes that persist, not just a transient pharmacological effect.

Honesty about variability: This is a peptide where placebo + small-cohort + selection-bias effects are particularly hard to disentangle. The Heij 2012 trial showed real effect vs placebo, but effect sizes were modest. Self-experimenters paying $80-150/month for ARA-290 are not blinded and want it to work. Subjective experience is consistent with a real but modest effect — not a "wow, this changed everything" peptide. The signal-to-noise is highest in users with clear small-fiber-pattern symptoms (burning, tingling, autonomic complaints) and lowest in users with primarily large-fiber complaints (motor weakness, classic numbness without burning).

For cubital tunnel-type peripheral nerve compression specifically: the user's described symptom is "pressure-based, nerve-feeling pain on soft surfaces" — this has a small-fiber component (pressure-evoked dysesthesia) but is primarily mechanical-compression-driven large-fiber pathology. The expected ARA-290 effect would be on the small-fiber pain quality (the burning/tingling sensation when the nerve is compressed) more than on the underlying compression itself. BPC-157's Schwann-cell + angiogenic mechanism is more directly addressing the compression-tissue level; ARA-290 would be addressing the small-fiber pain experience that emerges from that tissue state.

• Tolerance buildup: Minimal. The IRR is upregulated specifically at injury sites; chronic stimulation may eventually downregulate, but no human data on this.
• Recommended cycle: 4 weeks on, 4-8 weeks off. Up to 2 cycles per year for chronic-management indications.
• Reset protocol: No reset needed; peptide clears within hours.

Synergistic with

• bpc-157 — Mechanism-complementary (BPC-157 → VEGFR2 / NO / Schwann-cell / local angiogenesis; ARA-290 → IRR / anti-inflammatory / small-fiber regeneration). Reasonable to co-administer if a user wants to layer both signals at a peripheral nerve injury site. Caveat: unclear marginal benefit over BPC-157 alone for cubital tunnel — recommend BPC-157 + TB-500 cycle 1 first, add ARA-290 only if response is partial.
• tb-500 — Mechanism non-overlapping (TB-500 → systemic G-actin / cell-migration; ARA-290 → injury-site IRR signaling). Co-administration is theoretically additive but injection-burden becomes high (TB-500 2×/week + BPC-157 daily + ARA-290 daily = 9-10 injections per week). Pragmatically, run TB-500's 8-week cycle, then add ARA-290 in a separate 4-week cycle.
• ghk-cu — Different lane (skin/connective-tissue) but mechanism-non-conflicting. Useful if there's a parallel skin or connective-tissue target. Not a daily-priority for users in this archetype.
• semax / selank — Different lanes (CNS BBB-permeable Russian peptides). No interaction expected; non-conflicting co-administration.
• Anti-inflammatory infrastructure (curcumin, omega-3, NAC, vitamin C) — already in V4; mechanism-complementary, supports ARA-290's anti-inflammatory direction.

Avoid stacking with

• Exogenous EPO or EPO mimetics — redundant + reintroduces the erythropoietic risk ARA-290 was specifically designed to avoid.
• Active high-dose corticosteroids — theoretical interaction with the immune-modulation arm of ARA-290; not contraindicated but confounding.
• Chronic NSAIDs — same logic as for BPC-157; suppresses inflammatory-phase signaling that ARA-290 modulates. Use acetaminophen for pain control during cycle if needed.

Neutral / safe co-administration

• All V4 daily core supplements
• Modafinil, bromantane, Adamax/Semax, ALCAR, taurine, apigenin (V5 plans)
• Cerebrolysin cycles (different lane, no conflict)
• Standard MMA-relevant supplements
• Caffeine (V4 ramp)
• Creatine

• CYP enzymes: ARA-290 is a small peptide cleared by general peptidases — no significant CYP induction or inhibition. Does not affect modafinil (CYP3A4) or any other this archetype's typical stack member.
• Hormonal contraceptives: No interaction. Irrelevant for users in this archetype.
• Anticoagulants / antiplatelets: No documented interaction. Theoretical: if the IRR-only safety thesis fully holds, ARA-290 should not affect coagulation. Not a documented concern.
• Alcohol: No interaction (the user alcohol-free, non-issue).
• NSAIDs: Minimize during cycle for the same reason as BPC-157/TB-500 — chronic NSAIDs may dampen the inflammatory-phase signaling ARA-290 modulates.
• Other immune-modulating drugs (biologics for autoimmune disease, immunosuppressants): unclear interaction; not relevant for users in this archetype.

• Minimal published pharmacogenomic data. ARA-290 acts on a heterodimeric receptor (EPOR/βCR) and downstream JAK-STAT cascades. There is no single CYP polymorphism, transporter SNP, or receptor variant that documented-modifies its profile.
• Theoretical / indirect:
  • EPOR variants (rare polymorphisms) could in principle affect IRR signaling efficiency. No actionable data.
  • JAK2 V617F (a polycythemia vera-associated mutation) would be a hard contraindication if present — but this is rare and would already be flagged on a CBC showing baseline polycythemia.
  • Inflammation-axis variants (IL-6, TNF-α, NF-κB pathway) could in principle modify response. No actionable data.
• Action item post-23andMe (June 2026): No specific ARA-290-relevant variants to look for. Indirect: any predisposition to thrombosis (factor V Leiden, prothrombin G20210A) would slightly increase the importance of the CBC/hematocrit safety check during cycle, though ARA-290's mechanism does not directly produce thrombotic risk.

Cost math for users in this archetype (one 4-week cycle at 4 mg/day):

• 4 mg × 28 days = 112 mg total = 28 × 4 mg vials, or 14 × 8 mg vials
• At Limitless Life @ $130/8mg: 14 × $130 = $1,820 for the ARA-290 component
• That is substantially more expensive than BPC-157 + TB-500 combined. ARA-290 is a high-cost peptide due to lower production volume + specialty status.
• Alternative dosing math at 2 mg/day (if user accepts the lower-dose variant): 2 mg × 28 = 56 mg = 7 × 8 mg vials = $910. Still expensive.
• This cost profile is one of the reasons the verdict is WATCH-LIST not OPTIONAL-ADD — even if the user wanted to add ARA-290 to the cubital-tunnel protocol, the marginal benefit-per-dollar over BPC-157 alone is unclear.

Sourcing strategy if revisited:

• Order 2-3 weeks before planned cycle start; verify COA on every batch (HPLC purity ≥98%, mass spec confirming ~1257 Da, endotoxin <0.5 EU/mg).
• Cold chain: lyophilized powder shelf-stable short-term; refrigerate unopened vials and reconstituted vials. Use reconstituted within 30 days.
• Vendor consistency is more variable for ARA-290 than for BPC-157/TB-500 due to lower production volume — willing to wait for in-stock inventory at established vendors rather than chasing the cheapest in-stock option.

Quality verification on receipt:

• Sealed crimp-top vial, intact rubber stopper, lyophilized powder white/off-white
• Vial label matches order; lot number traceable to COA
• COA from independent third-party lab (HPLC + MS confirmation of correct molecular weight)
• If powder discolored, liquid in vial, or seal compromised → discard

Baseline (before cycle, if the user revisits)

• CBC + hematocrit + reticulocyte count — critical safety check. Hematocrit must NOT rise on cycle. This is the key biomarker safeguard distinguishing ARA-290 from EPO.
• hsCRP, IL-6 if available — anti-inflammatory baseline; would expect mild reduction on cycle.
• CMP (general organ-function safety baseline)
• Cubital tunnel objective baseline:
  • Grip dynamometer (R + L)
  • Pinch dynamometer (key pinch is ulnar-specific)
  • Tinel test at medial epicondyle (threshold to elicit paresthesia)
  • Phalen / elbow flexion test
  • 2-point discrimination at ring + small finger pads (most sensitive for small-fiber function)
  • Subjective burning/tingling/pressure-pain symptom scale (0-10)
• Family history thrombosis / polycythemia/JAK2 V617F context — TBD per the user profile; minor relevance given the IRR-only safety thesis but worth checking.

During use (week 2, week 4)

• CBC + hematocrit (week 4) — confirms no off-target erythropoiesis. Hard-stop trigger if hematocrit rises >2% from baseline.
• hsCRP (week 4) — would expect mild reduction.
• Repeat grip + pinch dynamometer, Tinel, Phalen, 2-point discrimination
• Subjective symptom diary (burning/tingling intensity, frequency, position triggers)

Post-cycle (4 weeks after stop)

• Repeat full objective battery + CBC
• Decide: meaningful improvement that persists (good response, hold and observe), partial improvement (consider second cycle), no improvement (drop ARA-290 from rotation)

Cycle-to-cycle if running multiple cycles per year

• Pre-cycle CBC + hsCRP + blood pressure each cycle
• Annual review of cumulative cycles + ongoing symptom-relevance vs alternatives